12:00 AM
 | 
Jan 10, 2011
 |  BC Week In Review  |  Company News  |  Deals

Immutep, GlaxoSmithKline deal

Immutep granted GlaxoSmithKline exclusive, worldwide rights to develop and commercialize autoimmune candidate IMP731 and any other human antibodies that deplete...

Read the full 78 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >